Estados Unidos · Agencias y tiempo real · PR Newswire

Full-Life Technologies Reports Encouraging Preliminary Phase 1 Safety and PSA Decline for FL-020 in mCRPC at ESMO 2026

Publicado por PR Newswire · Estados Unidos hace 1 h

Data updates from the ongoing Phase 1 dose-escalation study demonstrated promising therapeutic index in patients with mCRPC No dose-limiting toxicities observed; xerostomia has…

Leer el artículo completo en PR Newswire Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.prnewswire.com)

Full-Life Technologies Reports Encouraging Preliminary Phase 1 Safety and PSA Decline for FL-020 in mCRPC at ESMO 2026

También te puede interesar

The Ford Foundation, one of the world’s largest grantmakers, will throw more weight behind democracy

You.com Launches Inference Router, Bringing Enterprise-Grade Reliability to Open-Weight AI Models On Demand

Advancing Government Intelligence: Insights From the Data and Intelligence Training Forum

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows

Full-Life Technologies Reports Encouraging Preliminary Phase 1 Safety and PSA Decline for FL-020 in mCRPC at ESMO 2026

Compartir

También te puede interesar

The Ford Foundation, one of the world’s largest grantmakers, will throw more weight behind democracy

You.com Launches Inference Router, Bringing Enterprise-Grade Reliability to Open-Weight AI Models On Demand

Advancing Government Intelligence: Insights From the Data and Intelligence Training Forum

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows